| Deal value | $288M |
|---|---|
| Share of market cap | 12.2% |
Key highlights
- Issuance of 16,428,572 total shares of common stock at a public price of $17.50 per share
- Exercise in full of the underwriters' option to purchase an additional 2,142,857 shares
- Net proceeds of $269.7 million realized after deducting underwriting discounts and commissions
- Transaction led by Jefferies LLC, Leerink Partners LLC, and TD Securities (USA) LLC
- Capital infusion occurs as the company maintains a market capitalization of $2.36 billion
Details of the Offering
Arcus Biosciences, Inc. (NYSE: RCUS) finalized an underwritten public offering of 14,285,715 shares of common stock at a price of $17.50 per share. Concurrently, the underwriters exercised their 30-day option to purchase an additional 2,142,857 shares in full. The closing of the offering on October 23, 2026, resulted in the issuance of 16,428,572 shares. After accounting for underwriting discounts and estimated offering expenses, the company received approximately $269.7 million in net proceeds. Jefferies LLC, Leerink Partners LLC, and TD Securities (USA) LLC served as the representatives of the several underwriters for the transaction.
Strategic Rationale
The capital raise follows a series of public offerings by Arcus, including previous transactions in February 2025 and October 2025. By securing nearly $270 million in fresh capital, the company addresses the high operational costs associated with its clinical-stage oncology programs. The transaction occurred during a period where the stock's Relative Strength Index (RSI) reached 27.5, indicating technical oversold conditions. This proactive funding strategy allows the company to maintain its development momentum without immediate reliance on milestone-dependent payments or new partnership agreements, providing a buffer against market volatility in the biotechnology sector.
Financial Context
- The company previously guided that existing cash reserves would fund operations until at least the second half of 2028
- Full-year 2026 GAAP revenue guidance was established between $45 million and $55 million
- Quarterly revenue of $41.0 million is primarily derived from strategic collaborations rather than product sales
- The company reported annual revenue of $247.0 million for the prior fiscal year
- Net proceeds from this offering will supplement the existing cash and marketable securities balance
Down 9.0% since our story on 23 Oct: $18.52 when we broke it → $16.86 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $22.14 |
|---|---|
| 20 Oct | $23.75 |
| 21 Oct | $19.10 |
| 22 Oct | $19.36 |
| 23 Oct | $18.54 |
| 26 Oct | $17.76 |
| 27 Oct | $18.14 |
| 28 Oct | $18.39 |
| 29 Oct | $18.61 |
| 30 Oct | $18.19 |
| 2 Nov | $17.85 |
| 3 Nov | $18.91 |
| 4 Nov | $19.31 |
| 5 Nov | $17.69 |
| 6 Nov | $18.28 |
| 9 Nov | $18.95 |
| 10 Nov | $18.67 |
| 11 Nov | $18.80 |
| 12 Nov | $17.77 |
| 13 Nov | $17.43 |
| 16 Nov | $16.86 |
Business Overview
Arcus Biosciences is a California-based clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. The company’s research and development efforts target various biological pathways, including TIGIT, adenosine, and HIF-2a. As a clinical entity, Arcus does not currently have approved commercial products and generates revenue primarily through its collaboration agreement with Gilead Sciences. The company’s pipeline includes several late-stage candidates aimed at treating solid tumors. This latest capital injection supports the continued advancement of these candidates through complex clinical trials and regulatory filing preparations.
| Date | Announcement | Amount |
|---|---|---|
| 21 Oct 2026 | Underwritten public offering of common stockSource: stockanalysis.com | $250.0 Million |
| 30 Oct 2025 | Underwritten public offering of common stockSource: investors.arcusbio.com | $250.0 Million |
| 18 Feb 2025 | Underwritten public offering of common stockSource: investors.arcusbio.com | $150.0 Million |
| Share price | $18.52 |
|---|---|
| Market cap | $2.4B |
| Revenue (annual) | $247M |
| 1-month price change | -29.82% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Arcus Biosciences, Inc. announcing the closing of a $287.5 million public offering of common stock.
Track Arcus Biosciences, Inc. live
Get the next Arcus Biosciences, Inc. SEC filing seconds after it lands.




